Provider Resources

Here is a list of helpful tools, information, and resources for mental health, gynecologists, and other health care providers. These tools are essential to making an accurate diagnosis, planning a course of treatment, and improving patient outcomes.

Are you a patient, friend, or family member? Click here for patient and partner resources.

Daily Record of Severity of Problems (DRSP) 

The DRSP is a assessment instruments to establish diagnosis of PMDD. Prospective daily monitoring of symptoms for two consecutive menstrual cycles is a clinical requirement to meet DSM-IV criteria. As none of PMDD’s symptoms are unique to the disorder, patients need to keep a daily diary of symptoms for at least two (2) menstrual cycles to establish a relationship between the onset of symptoms and the premenstrual period, in addition to the absence of symptoms or a chronic underlying disorder during the follicular phase.


Symptom Tracker App

Me v PMDD makes symptom tracking for Premenstrual Dysphoric Disorder incredibly simple and is accompanied by easy-to-read symptom graphs that can help patients and providers understand and more effectively treat PMDD. This free app is easy to use and connects patients with valuable resources for taking control of life with PMDD.

About PMDD Printable.png

PMDD Overview

This free information guide is a great overview on what PMDD is and isn't. This guide is an excellent resource to share with family, friends, caregivers, and doctors to aid in gathering support and understand. It is also a valuable tool for developing your own insight to PMDD to aid in your treatment journey.


Algorithm for the Management of PMDD



Treatment Guidelines for PMDD and PME



Management of Premenstrual Syndrome, RCOG Guidelines

Since the first edition, there has been considerable work by the International Society for Premenstrual Disorders and the National Association for Premenstrual Syndrome to achieve consensus on the recognition, diagnosis, classification and management of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).


The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis

Gonadotrophin-releasing hormone agonists analogues (GnRHa) are an example of a group of drugs that suppress ovarian function, which is believed to be the trigger for premenstrual syndrome/premenstrual dysphoric disorder.

This resource will be moving to soon.


Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations

There is a new appreciation of the perimenopause as a window of vulnerability for the development of both depressive symptoms and major depressive episodes. However, clinical recommendations on how to identify, characterize and treat clinical depression are lacking. To address this gap, an expert panel was convened to systematically review the published literature and develop guidelines on the evaluation and management of perimenopausal depression.

This resource will be moving to soon.


Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome

When first-line medical treatments fail and a patient has completed her family, a hysterectomy may be a suitable course of action. Despite few reports of TAH/BSO as a treatment for severe PMS, we have found surgery, coupled with appropriate HRT, to be an extremely effective and well-accepted permanent cure for PMS.

This resource will be moving to soon.


The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder

In this study, lymphoblastoid cell line cultures (LCLs) from women with PMDD and asymptomatic controls were compared via whole-transcriptome sequencing (RNA-seq) during untreated (ovarian steroid-free) conditions and following hormone treatment.

This resource will be moving to soon.